Pricing Log in Create free account
Saturday 17 October 2026 Export MXCT’s income statement to Excel — free account

MaxCyte, Inc.

MXCT Healthcare Medical Devices

MaxCyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.0 million, down 14.5% from fiscal 2024. In the quarter to June 2026, revenue fell 14.5%, EPS grew 33.3% and free cash flow grew 54.7%, each against the same quarter a year earlier.

1.30 0.00 0.00%
Market cap
$134.2M
P/E
0.0×
Fwd P/E
−6.1×
Dividend yield
—
F-score
2/9
Altman Z
1.32
Beneish M
−2.89
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.01
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — 1 — — — — — — —
Insider Ownership 11.29%

Capital & Financial Ratios $m

Market Cap 134.17
Revenue 31.05
Net Income (35.64)
Free Cash Flow (23.64)
Net Debt (105.69)
Current Ratio 12.26 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (6.08) (negative: loss-making)
P/S ratio 4.47
P/B ratio 0.87
Past 5Y EPS Growth —
This Y EPS Growth 34.78% (at or above 15%: strong)
Next Y EPS Growth 6.91%
Next Y revenue growth 49.70% (at or above 10%: strong)
Next 5Y EPS Growth 17.03% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.2×, against a ten-year median of 6.5×; over the ten years it ranged from −0.8× in 2026 to 47.5× in 2021.
P/S against its own 10 years 14.43%
10-year low 10-year high
P/B against its own 10 years 13.24%
10-year low 10-year high
EV/Sales against its own 10 years 10.12%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2026 Powerpack
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 168 154 103 106
Receivables 6 5 4 4
Inventory 12 9 8 8
Other — — — 0
190 172 118 121
2023 2024 2025 Q'26
Payables 1 1 1 2
ST’ Debt — — — —
Other — — — —
18 16 14 10

Compound Annual Growth %

10y 5y 3y
Sales — 4.76% (9.30%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 38.85% (12.27%)

Revenue $m

Mar Jun Sep Dec Year
’26 10 7 — — —
’25 10 9 7 7 33
’24 11 10 8 9 39
’23 9 9 8 16 41
’22 12 10 11 12 44
’21 6 7 10 10 34
’20 6 5 7 9 26
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) (5) — — —
’25 (14) (10) (7) (3) (34)
’24 (11) (5) (4) (8) (28)
’23 (4) (10) (8) 1 (22)
’22 (4) 1 (6) (6) (15)
’21 (5) (4) (1) (1) (11)
’20 (5) (1) (1) (2) (9)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) (5) — — —
’25 (15) (10) (8) (3) (36)
’24 (11) (5) (5) (8) (29)
’23 (6) (11) (9) 0 (25)
’22 (10) (6) (9) (281) (306)
’21 (5) (5) (2) (267) (279)
’20 (6) (1) (1) (2) (11)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.04) (0.08) — — —
’25 (0.10) (0.12) (0.12) (0.09) (0.42)
’24 (0.09) (0.09) (0.11) (0.10) (0.39)
’23 (0.11) (0.10) (0.11) (0.05) (0.37)
’22 (0.04) (0.08) (0.06) (0.05) (0.23)
’21 (0.09) (0.05) (0.03) (0.05) (0.21)
’20 (0.05) (0.05) (0.04) (0.03) (0.17)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 1.63 1.63 5.85 3.36 2.45 3.17 1.26

Analyst estimates 2026–2028

Powerpack
High — — — 1.63 6.13 17.44 10.88 6.02 5.55 5.20
People
People Employees — — — — 65 84 125 143 114 91
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.40 0.40 0.35 0.29 0.34 0.36
Income, $m
Income, $m Revenue 11 19 21 22 26 34 44 41 39 33
Gross margin, % 89.34 89.61 88.96 88.44 89.43 89.24 88.48 88.51 81.62 81.16
EBT (3) (13) (11) (13) (12) (19) (24) (38) (41) (45)
EBT margin, % (27.27) (70.91) (53.21) (59.64) (45.15) (56.30) (53.25) (91.85) (106.29) (135.14)
Net income (3) 0 (11) (13) (12) (19) (24) (38) (41) (45)
Depreciation 0 0 0 1 1 1 0 (3) (2) 5
Per share, $
Per share, $ Revenue 0.34 0.39 0.42 0.38 0.38 0.37 0.44 0.40 0.37 0.31
Earnings (0.11) (0.27) (0.22) (0.23) (0.17) (0.21) (0.23) (0.37) (0.39) (0.42)
Cash flow (0.06) (0.27) (0.26) (0.16) (0.13) (0.12) (0.15) (0.21) (0.26) (0.32)
Capex 0.00 0.00 0.00 (0.02) (0.03) (2.96) (2.86) (0.04) (0.02) (0.02)
Free cash flow (0.06) (0.27) (0.26) (0.18) (0.16) (3.08) (3.01) (0.25) (0.28) (0.34)
Book value 0.15 0.54 0.31 0.24 0.48 2.90 2.50 2.25 1.97 1.61
Shares, m 34 49 51 56 69 91 102 103 105 106
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 0.00 0.00 16.27 27.24 11.76 12.51 11.29 5.00
P/B 0.00 0.00 0.00 0.00 12.82 3.51 2.05 2.22 2.11 0.96
EV/Sales 0.00 0.00 0.00 0.00 15.13 19.86 6.74 8.55 7.42 2.02
EV/FCF 0.00 0.00 0.00 0.00 (36.48) (2.41) (0.98) (13.91) (9.79) (1.85)
Cash, $m
Cash, $m Operating cash flow (2) (13) (13) (9) (9) (11) (15) (22) (28) (34)
Capex 0 (1) (1) (1) (2) (269) (291) (4) (2) (2)
Free cash flow (2) (13) (13) (10) (11) (279) (306) (25) (29) (36)
Balance, $m
Balance, $m Working capital 10 31 20 15 34 255 237 172 156 104
Total debt 5 7 6 5 5 7 19 — — —
Net debt (7) (27) (12) (12) (30) (255) (227) (168) (154) (103)
Shareholders’ equity 5 26 16 14 33 263 254 232 206 171
Returns, %
Returns, % ROA (14.86) (166.91) (48.21) (42.21) (28.90) (11.36) (8.26) (13.67) (16.17) (20.20)
ROIC 0.00 0.00 0.00 (434.02) (204.47) (144.75) (64.22) (47.26) (61.81) (47.39)
ROE (28.58) (84.92) (53.85) (87.88) (50.47) (12.89) (9.12) (15.60) (18.73) (23.63)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

MaxCyte, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RXST RxSight, Inc. $194.2M — (loss-making) — (loss-making) +0.31% (above 0%: growing) n/m −94.39% (below 0%: shrinking) 76.72% (40.81%) Compare
INGN Inogen, Inc $167.1M — (loss-making) — (loss-making) +3.04% (above 0%: growing) n/m −51.15% (below 0%: shrinking) 45.51% (5.36%) Compare
STIM Neuronetics, Inc. $148.6M — (loss-making) — (loss-making) +9.08% (above 0%: growing) n/m +62.06% (above 0%: growing) 51.06% (3.61%) Compare
QTRX Quanterix Corporation $145.2M — (loss-making) — (loss-making) +34.44% (above 0%: growing) n/m +18.92% (above 0%: growing) 38.52% (150.22%) Compare
MXCT MaxCyte, Inc. $134.2M — (loss-making) — (loss-making) −14.53% (below 0%: shrinking) n/m +54.74% (above 0%: growing) 76.96% (140.72%)
OWLT Owlet, Inc. $129.8M — (loss-making) — (loss-making) +29.94% (above 0%: growing) n/m +55.74% (above 0%: growing) 64.44% 5.14% Compare
APYX Apyx Medical Corporation $107.8M — (loss-making) — (loss-making) +22.08% (above 0%: growing) n/m −137.38% (below 0%: shrinking) 63.89% (13.01%) Compare
LUCD Lucid Diagnostics Inc. $105.7M — (loss-making) — (loss-making) +26.74% (above 0%: growing) n/m −7.04% (below 0%: shrinking) 1.97% (868.45%) Compare
ZOMDF Zomedica Corp. $95.4M — (loss-making) — (loss-making) +36.59% (above 0%: growing) n/m +40.48% (above 0%: growing) 63.51% (42.92%) Compare
Median of peers $137.5M — — +24.41% — +5.94% 57.29% (26.91%)

All 149 Medical Devices stocks →

MaxCyte, Inc. (MXCT) key facts

  • Concern: MaxCyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.0 million, down 14.5% from fiscal 2024.
  • Concern: MaxCyte, Inc. reported a net loss of $44.6 million, or a loss of $0.42 per share, for fiscal 2025.
  • MaxCyte, Inc. (MXCT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, MXCT traded at $1.30, a market capitalization of $134.2 million.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.5× sales.
  • Return on equity was −23.6% and debt-to-equity 0.00.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 1.32 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

MaxCyte, Inc. (MXCT) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/MXCT · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com